Challenges and Opportunities in the Management of Onychomycosis

Julia K Christenson, Gregory M Peterson, Mark Naunton, Mary Bushell, Sam Kosari, Kavya E Baby, Jackson Thomas, Julia K Christenson, Gregory M Peterson, Mark Naunton, Mary Bushell, Sam Kosari, Kavya E Baby, Jackson Thomas

Abstract

Onychomycosis is an increasingly common fungal nail infection, chiefly caused by dermatophyte fungi. The disease is notoriously difficult to treat due to the deep-seated nature of fungi within the nail plate, prolonged treatment requirements, poor patient adherence and frequent recurrences. Given the poor efficacy of currently available topical and systemic therapies, there is a renewed interest in exploring alternative treatment modalities for onychomycosis. Natural therapies, physical treatments and various combination therapies have all shown potential for the management of onychomycosis, though research on many of these methods is still in preliminary stages. Further large, well-designed, randomised controlled trials are necessary to confirm the efficacy of these novel treatments in order to make formal recommendations regarding their use in the management of onychomycosis.

Keywords: alternative treatment; combination therapy; fungi; infection; nail; onychomycosis; treatment.

Conflict of interest statement

The authors declare no conflict of interest

Figures

Figure 1
Figure 1
Onychomycosis treatment algorithm (modified from Thomas et al. [4]).

References

    1. Scher R.K. Onychomycosis is more than a cosmetic problem. Br. J. Dermatol. 1994;130:15. doi: 10.1111/j.1365-2133.1994.tb06087.x.
    1. Gupta A.K., Gupta G., Jain H.C., Lynde C.W., Foley K.A., Daigle D., Cooper E.A., Summerbell R.C. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30,000 patients visiting physicians’ offices. J. Eur. Acad. Dermatol. Venereol. 2016;30:1567–1572. doi: 10.1111/jdv.13677.
    1. Elewski B.E., Tosti A. Risk factors and comorbidities for onychomycosis: Implications for treatment with topical therapy. J. Clin. Aesthet. Dermatol. 2015;8:38–42.
    1. Thomas J., Jacobson G.A., Narkowicz C.K., Peterson G.M., Burnet H., Sharpe C. Toenail onychomycosis: An important global disease burden. J. Clin. Pharm. Ther. 2010;35:497–519. doi: 10.1111/j.1365-2710.2009.01107.x.
    1. Lipner S.R., Scher R.K. Part I: Onychomycosis: Clinical overview and diagnosis. J. Am. Acad. Dermatol. 2018 doi: 10.1016/j.jaad.2018.03.062.
    1. Ghannoum M., Salem I., Christensen L. Epidemiology of onychomycosis. In: Rigopoulos D., Elewski B., Richert B., editors. Onychomycosis. John Wiley & Sons; Hoboken, NJ, USA: 2018.
    1. Lee W.J., Kim S.L., Jang Y.H., Lee S.J., Kim D.W., Bang Y.J., Jun J.B. Increasing prevalence of trichophyton rubrum identified through an analysis of 115,846 cases over the last 37 years. J. Korean Med. Sci. 2015;30:639–643. doi: 10.3346/jkms.2015.30.5.639.
    1. Piérard G.E. Spores, sporodochia and fomites in onychomycosis. Dermatology. 2006;213:169–172. doi: 10.1159/000093862.
    1. Eba M., Njunda A.L., Mouliom R.N., Kwenti E.T., Fuh A.N., Nchanji G.T., Atashili J. Onychomycosis in diabetic patients in fako division of cameroon: Prevalence, causative agents, associated factors and antifungal sensitivity patterns. BMC Res. Notes. 2016;9:494. doi: 10.1186/s13104-016-2302-1.
    1. Lipner S.R., Scher R.K. Part II: Onychomycosis: Treatment and prevention of recurrence. J. Am. Acad. Dermatol. 2018:S0190–S9622. doi: 10.1016/j.jaad.2018.05.1260.
    1. Elewski B.E., Rich P., Pollak R., Pariser D.M., Watanabe S., Senda H., Ieda C., Smith K., Pillai R., Ramakrishna T., et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J. Am. Acad. Dermatol. 2013;68:600–608. doi: 10.1016/j.jaad.2012.10.013.
    1. Elewski B.E., Aly R., Baldwin S.L., González Soto R.F., Rich P., Weisfeld M., Wiltz H., Zane L.T., Pollak R. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. J. Am. Acad. Dermatol. 2015;73:62–69. doi: 10.1016/j.jaad.2015.04.010.
    1. Kreijkamp-Kaspers S., Hawke K., Guo L., Kerin G., Bell-Syer S.E., Magin P., Bell-Syer S.V., van Driel M.L. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst. Rev. 2017;7:Cd010031. doi: 10.1002/14651858.CD010031.pub2.
    1. Yan J., Wang X., Chen S. Systematic review of severe acute liver injury caused by terbinafine. Int. J. Clin. Pharm. 2014;36:679–683. doi: 10.1007/s11096-014-9969-y.
    1. Gupta A.K., Daigle D., Foley K.A. Network meta-analysis of onychomycosis treatments. Skin Appendage Disord. 2015;1:74–81. doi: 10.1159/000433473.
    1. Gupta A.K., Daigle D., Carviel J.L. The role of biofilms in onychomycosis. J. Am. Acad. Dermatol. 2016;74:1241–1246. doi: 10.1016/j.jaad.2016.01.008.
    1. Scher R.K., Baran R. Onychomycosis in clinical practice: Factors contributing to recurrence. Br. J. Dermatol. 2003;149:5–9. doi: 10.1046/j.1365-2133.149.s65.5.x.
    1. Tosti A., Elewski B.E. Onychomycosis: Practical approaches to minimize relapse and recurrence. Skin Appendage Disord. 2016;2:83–87. doi: 10.1159/000448056.
    1. Halteh P., Scher R.K., Lipner S.R. Over-the-counter and natural remedies for onychomycosis: Do they really work? Cutis. 2016;98:e16–e25.
    1. Szepietowski J.C., Reich A., Garlowska E., Kulig M., Baran E. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: A survey of 2761 patients. Arch. Dermatol. 2006;142:1279–1284. doi: 10.1001/archderm.142.10.1279.
    1. Bhatta A.K., Keyal U., Wang X.L. Photodynamic therapy for onychomycosis: A systematic review. Photodiagn. Photodyn. Ther. 2016;15:228–235. doi: 10.1016/j.pdpdt.2016.07.010.
    1. Gupta A.K., Versteeg S.G. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. J. Eur. Acad. Dermatol. Venereol. 2017;31:1111–1118. doi: 10.1111/jdv.14212.
    1. Carson C.F., Hammer K.A., Riley T.V. Melaleuca alternifolia (tea tree) oil: A review of antimicrobial and other medicinal properties. Clin. Microbiol. Rev. 2006;19:50–62. doi: 10.1128/CMR.19.1.50-62.2006.
    1. Hammer K.A., Carson C.F., Riley T.V. In vitro activity of Melaleuca alternifolia (tea tree) oil against dermatophytes and other filamentous fungi. J. Antimicrob. Chemother. 2002;50:195–199. doi: 10.1093/jac/dkf112.
    1. Gayoso C.W., Lima E.O., Oliveira V.T., Pereira F.O., Souza E.L., Lima I.O., Navarro D.F. Sensitivity of fungi isolated from onychomycosis to eugenia cariophyllata essential oil and eugenol. Fitoterapia. 2005;76:247–249. doi: 10.1016/j.fitote.2004.12.005.
    1. Flores F.C., Beck R.C.R., da Silva C.B. Essential oils for treatment for onychomycosis: A mini-review. Mycopathologia. 2016;181:9–15. doi: 10.1007/s11046-015-9957-3.
    1. Romero-Cerecero O., Zamilpa A., Jimenez-Ferrer J.E., Rojas-Bribiesca G., Roman-Ramos R., Tortoriello J. Double-blind clinical trial for evaluating the effectiveness and tolerability of ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox. Planta Med. 2008;74:1430–1435. doi: 10.1055/s-2008-1081338.
    1. Romero-Cerecero O., Roman-Ramos R., Zamilpa A., Jimenez-Ferrer J.E., Rojas-Bribiesca G., Tortoriello J. Clinical trial to compare the effectiveness of two concentrations of the ageratina pichinchensis extract in the topical treatment of onychomycosis. J. Ethnopharmacol. 2009;126:74–78. doi: 10.1016/j.jep.2009.08.007.
    1. Sipponen P., Sipponen A., Lohi J., Soini M., Tapanainen R., Jokinen J.J. Natural coniferous resin lacquer in treatment of toenail onychomycosis: An observational study. Mycoses. 2013;56:289–296. doi: 10.1111/myc.12019.
    1. Auvinen T., Tiihonen R., Soini M., Wangel M., Sipponen A., Jokinen J.J. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: A prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial. Br. J. Dermatol. 2015;173:940–948. doi: 10.1111/bjd.13934.
    1. Veiga F.F., Gadelha M.C., da Silva M.R.T., Costa M.I., Kischkel B., de Castro-Hoshino L.V., Sato F., Baesso M.L., Voidaleski M.F., Vasconcellos-Pontello V., et al. Propolis extract for onychomycosis topical treatment: From bench to clinic. Front. Microbiol. 2018;9:779. doi: 10.3389/fmicb.2018.00779.
    1. Derby R., Rohal P., Jackson C., Beutler A., Olsen C. Novel treatment of onychomycosis using over-the-counter mentholated ointment: A clinical case series. J. Am. Board Fam. Med. 2011;24:69–74. doi: 10.3122/jabfm.2011.01.100124.
    1. Snell M., Klebert M., Onen N.F., Hubert S. A novel treatment for onychomycosis in people living with hiv infection: Vicks vaporub is effective and safe. J. Assoc. Nurses AIDS Care. 2016;27:109–113. doi: 10.1016/j.jana.2015.10.004.
    1. Buck D.S., Nidorf D.M., Addino J.G. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. J. Fam. Pract. 1994;38:601–605.
    1. Syed T.A., Qureshi Z.A., Ali S.M., Ahmad S., Ahmad S.A. Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Trop. Med. Int. Health. 1999;4:284–287. doi: 10.1046/j.1365-3156.1999.00396.x.
    1. Menendez S., Falcon L., Maqueira Y. Therapeutic efficacy of topical oleozon(r) in patients suffering from onychomycosis. Mycoses. 2011;54:e272–e277. doi: 10.1111/j.1439-0507.2010.01898.x.
    1. Parekh M., Ramaiah G., Pashilkar P., Ramanujam R., Johnston P., Ilag L.L. A pilot single centre, double blind, placebo controlled, randomized, parallel study of calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis. BMC Complement. Altern. Med. 2017;17:464. doi: 10.1186/s12906-017-1970-2.
    1. Harris F., Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med. Res. Rev. 2012;32:1292–1327. doi: 10.1002/med.20251.
    1. Gupta A.K., Simpson F.C. New pharmacotherapy for the treatment of onychomycosis: An update. Expert Opin. Pharmacother. 2015;16:227–236. doi: 10.1517/14656566.2015.993380.
    1. Simmons B.J., Griffith R.D., Falto-Aizpurua L.A., Nouri K. An update on photodynamic therapies in the treatment of onychomycosis. J. Eur. Acad. Dermatol. Venereol. 2015;29:1275–1279. doi: 10.1111/jdv.12950.
    1. Figueiredo Souza L.W., Souza S.V., Botelho A.C. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. Dermatol. Ther. 2014;27:43–47. doi: 10.1111/dth.12042.
    1. Heinlin J., Maisch T., Zimmermann J.L., Shimizu T., Holzmann T., Simon M., Heider J., Landthaler M., Morfill G., Karrer S. Contact-free inactivation of trichophyton rubrum and microsporum canis by cold atmospheric plasma treatment. Future Microbiol. 2013;8:1097–1106. doi: 10.2217/fmb.13.86.
    1. Xiong Z., Roe J., Grammer T.C., Graves D.B. Plasma treatment of onychomycosis. Plasma Process. Polym. 2016;13:588–597. doi: 10.1002/ppap.201600010.
    1. Lipner S.R., Friedman G., Scher R.K. Pilot study to evaluate a plasma device for the treatment of onychomycosis. Clin. Exp. Dermatol. 2017;42:295–298. doi: 10.1111/ced.12973.
    1. Bhatta A.K., Keyal U., Wang X., Gellen E. A review of the mechanism of action of lasers and photodynamic therapy for onychomycosis. Lasers Med. Sci. 2017;32:469–474. doi: 10.1007/s10103-016-2110-9.
    1. Therapeutic Goods Administration Public Summary for Surgical Diode Laser System. [(accessed on 20 June 2017)]; Available online: .
    1. Francuzik W., Fritz K., Salavastru C. Laser therapies for onychomycosis—Critical evaluation of methods and effectiveness. J. Eur. Acad. Dermatol. Venereol. 2016;30:936–942. doi: 10.1111/jdv.13593.
    1. Hollmig S.T., Rahman Z., Henderson M.T., Rotatori R.M., Gladstone H., Tang J.Y. Lack of efficacy with 1064-nm neodymium:Yttrium-aluminum-garnet laser for the treatment of onychomycosis: A randomized, controlled trial. J. Am. Acad. Dermatol. 2014;70:911–917. doi: 10.1016/j.jaad.2013.12.024.
    1. Mikailov A., Cohen J., Joyce C., Mostaghimi A. Cost-effectiveness of confirmatory testing before treatment of onychomycosis. JAMA Dermatol. 2016;152:276–281. doi: 10.1001/jamadermatol.2015.4190.
    1. Bristow I.R. The effectiveness of lasers in the treatment of onychomycosis: A systematic review. J. Foot Ankle Res. 2014;7:34. doi: 10.1186/1757-1146-7-34.
    1. Liddell L.T., Rosen T. Laser therapy for onychomycosis: Fact or fiction? J. Fungi. 2015;1:44–54. doi: 10.3390/jof1010044.
    1. Gupta A.K., Cernea M., Foley K.A. Improving cure rates in onychomycosis. J. Cutan. Med. Surg. 2016;20:517–531. doi: 10.1177/1203475416653734.
    1. Nair A.B., Kim H.D., Chakraborty B., Singh J., Zaman M., Gupta A., Friden P.M., Murthy S.N. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J. Pharm. Sci. 2009;98:4130–4140. doi: 10.1002/jps.21711.
    1. Gupta A.K., Versteeg S.G., Shear N.H. Onychomycosis in the 21st century: An update on diagnosis, epidemiology, and treatment. J. Cutan. Med. Surg. 2017;21:525–539. doi: 10.1177/1203475417716362.
    1. Park K.Y., Suh J.H., Kim B.J., Kim M.N., Hong C.K. Randomized clinical trial to evaluate the efficacy and safety of combination therapy with short-pulsed 1064-nm neodymium-doped yttrium aluminium garnet laser and amorolfine nail lacquer for onychomycosis. Ann. Dermatol. 2017;29:699–705. doi: 10.5021/ad.2017.29.6.699.
    1. Zhang J., Lu S., Huang H., Li X., Cai W., Ma J., Xi L. Combination therapy for onychomycosis using a fractional 2940-nm er: Yag laser and 5% amorolfine lacquer. Lasers Med. Sci. 2016;31:1391–1396. doi: 10.1007/s10103-016-1990-z.
    1. Lim E.H., Kim H.R., Park Y.O., Lee Y., Seo Y.J., Kim C.D., Lee J.H., Im M. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J. Am. Acad. Dermatol. 2014;70:918–923. doi: 10.1016/j.jaad.2014.01.893.
    1. Xu Y., Miao X., Zhou B., Luo D. Combined oral terbinafine and long-pulsed 1064-nm nd: Yag laser treatment is more effective for onychomycosis than either treatment alone. Dermatol. Surg. 2014;40:1201–1207. doi: 10.1097/DSS.0000000000000157.
    1. Li Y., Xu J., Zhao J.Y., Zhuo F.L. Self-controlled study of onychomycosis treated with long-pulsed nd: Yag 1064-nm laser combined with itraconazole. Chin. Med. J. 2016;129:1929–1934.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj